VISEN PHARMA-B: 2024 Annual Report

Weishen Pharmaceutical announced its 2024 annual performance, reporting a net loss of 0.1822 billion yuan, narrowing by 27.0% compared to the 0.2496 billion yuan loss in 2023. Research and development expenditure reached 90.5 million yuan. As of December 31, 2024, the company holds cash of 0.2036 billion yuan, with operating cash flow at -0.1409 billion yuan.The company’s core product, Lonapegsomatropin, submitted its listing application to the National Medical Products Administration in the first quarter of 2024 and has been accepted, with commercialization expected in the second half of 2025. Additionally, Palopegteriparatide has completed critical Phase III clinical trials, and Navepegritide has finished Phase II clinical trials.Looking ahead, Weishen Pharmaceutical will focus on advancing the commercialization preparations for core products, continuously promote the development of its product pipeline, and strengthen local production capacity construction. The company currently has 58 employees, 66% of whom are female, and has established a comprehensive risk management system, committed to enhancing corporate governance.

Weishen Pharmaceutical announced its 2024 annual performance, reporting a net loss of 0.1822 billion yuan, narrowing by 27.0% compared to the 0.2496 billion yuan loss in 2023. Research and development expenditure reached 90.5 million yuan. As of December 31, 2024, the company holds cash of 0.2036 billion yuan, with operating cash flow at -0.1409 billion yuan.The company’s core product, Lonapegsomatropin, submitted its listing application to the National Medical Products Administration in the first quarter of 2024 and has been accepted, with commercialization expected in the second half of 2025. Additionally, Palopegteriparatide has completed critical Phase III clinical trials, and Navepegritide has finished Phase II clinical trials.Looking ahead, Weishen Pharmaceutical will focus on advancing the commercialization preparations for core products, continuously promote the development of its product pipeline, and strengthen local production capacity construction. The company currently has 58 employees, 66% of whom are female, and has established a comprehensive risk management system, committed to enhancing corporate governance.